Inhibitors of hepatitis C virus NS3·4A protease. Part 3: P2 proline variants

https://doi.org/10.1016/j.bmcl.2004.01.078Get rights and content

Abstract

We recently described the identification of an optimized α-ketoamide warhead for our series of HCV NS3·4A inhibitors. We report herein a series of HCV protease inhibitors incorporating 3-alkyl-substituted prolines in P2. These compounds show exceptional enzymatic and cellular potency given their relatively small size. The marked enhancement of activity of these 3-substituted proline derivatives relative to previously reported 4-hydroxyproline derivatives constitutes additional evidence for the importance of the S2 binding pocket as the defining pharmacophore for inhibition of the NS3·4A enzyme.

A series of potent HCV NS3·4A protease inhibitors incorporating novel 3-substituted proline moieties at the P2 position are described.

  1. Download : Download full-size image

References (15)

  • A. Johansson et al.

    Bioorg. Med. Chem.

    (2003)
    R. Beevers et al.

    Bioorg. Med. Chem. Lett.

    (2002)
  • J.D. Dunitz

    Science

    (1994)
  • Perni, R.; Court, J.; O'Malley, E.; Rao, B. G., PCT WO 01/74768...
  • C. Herdeis et al.

    Tetrahedron: Asymmetry

    (1992)
  • M. Hashimoto et al.

    Tetrahedron

    (1996)
  • J.K. Thottathil et al.

    J. Org. Chem.

    (1986)
  • F. Narjes et al.

    Exp. Opin. Invest. Drugs

    (2003)
    For a comprehensive recent review see: Perni, R. B.; Kwong, A. D. In Progress in Medicinal Chemistry; King F. D.,...
There are more references available in the full text version of this article.

Cited by (0)

View full text